Study to Evaluate Safety Tolerability and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

  • STATUS
    Recruiting
  • End date
    Mar 31, 2021
  • participants needed
    84
  • sponsor
    Sinovent Pty Ltd.
Updated on 29 July 2020
body mass index
imipenem
cilastatin

Summary

This is a 3-part, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy male subjects. In part 1, subjects will receive a single dose of XNW4107. In part 2, subjects will receive XNW4107 for 7 days. In Part 3, subjects will receive XNW4107 in combination with imipenem/cilastatin for 14 days.

Details
Treatment XNW4107
Clinical Study IdentifierNCT04482569
SponsorSinovent Pty Ltd.
Last Modified on29 July 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 65 yrs?
Are you male?
Do you have any of these conditions: Bacterial Infections or Bacterial Infection?
Healthy male adults aged 18-65 years
Body Mass Index (BMI) between 18.5 - 32.0, inclusive
In good general health, as determined by the Investigator, based on medical history, physical examination, 12 lead electrocardiogram (ECG), vital sign (VS) measurements, and laboratory test results
Normal blood pressure (BP), defined as: systolic BP (SBP) 90 mmHg and 140 mmHg; and diastolic BP (DBP) <90 mmHg at the time of Screening
Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subject) in addition to an acceptable method (female partner) of contraception for the duration of the study and for at least 90 days post last dose
Negative serology results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus antibody (HIV Ab), hepatitis E immunoglobulin M antibody (IgM anti HEV), and Treponema pallidum antibody chemiluminescent immunoassay (TP IA)
Negative serology results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus antibody (HIV Ab), hepatitis E immunoglobulin M antibody (IgM anti HEV), and Treponema pallidum antibody chemiluminescent immunoassay (TP IA)
Non smoker (with no use of other tobacco or nicotine containing products, in any form), as documented by history (no nicotine within 3 months prior to Screening)
Negative results for drugs of abuse, alcohol, and cotinine at Screening and Admission

Exclusion Criteria

History of clinically significant psychiatric disorder within the past 5 years
History of stroke, chronic seizures, or other major neurological disorder
History or evidence of drug/alcohol abuse within 1 year prior to Screening
History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or disease
History of cancer (malignancy)
History of any illness that, in the opinion of the study investigator, may confound the results of the study or pose additional risk to the subject if he participates in the study
Administration of another investigational medication within 30 days (or 5 half lives, whichever is longer) prior to study drug administration
Participation in an investigational device study within 30 days prior to study drug administration
Excessive consumption of alcohol, defined as >3 alcoholic beverages per day (10 ounces of beer [284 mL], 4 ounces of wine [125 mL], or 1 ounce of distilled spirits [25 mL] is approximately equivalent to 1 alcoholic beverage)
Excessive consumption of coffee, tea, cola, or other caffeinated beverages; excessive consumption is defined as >6 servings per day (1 serving contains approximately 120 mg caffeine)
History and/or family history of congenital long QT syndrome, unexplained syncope, or other additional risks of Torsade de Pointes or sudden premature death
Any ECG abnormality considered to be clinically significant by the principal investigator (PI)/designee
Glomerular filtration rate (GFR) 80 mL/min/1.73 m2, as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation
Ongoing liver disease or unexplained liver function test (LFT) elevations
History of hypersensitivity to lactam antibiotics (including, but not limited to imipenem)
History of significant multiple and/or severe allergies (including latex allergy)
Loss or donation of blood (approximately 500 mL) within 60 days prior to study drug administration on Day 1, or donation of bone marrow or peripheral stem cells within 90 days prior to study drug administration on Day 1
History of infectious disease within 28 days prior to study drug administration on Day 1 that, in the opinion of the investigator, would affect the subject's ability to participate in the trial
Venous access considered inadequate for PK sample collection and IV infusion; history or evidence of adverse symptoms associated with IV access, phlebotomy, or blood donation
Employee or family member of the investigator, study site personnel, or sponsor
Any other clinically relevant abnormality in the opinion of the investigators from the following: medical and/or surgical history, physical examination, vital signs, 12-lead ECG, serum chemistry, hematology, and urinalysis
Any other reason that, in the opinion of the investigator, would render the subject unsuitable for study enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet